The Impact of MicroRNA 23/27 on Muscle Atrophy in Diabetic Mice

Elizabeth Marie Escobar, Xiaonan Wang, Faten HassounahThe FASEB Journal 2017 · DOI

Abstract

Diabetic nephropathy is the one of the major causes of morbidity and mortality in diabetes mellitus. Muscle atrophy is a serious consequence of diabetic nephropathy and other catabolic diseases. This study tests whether microRNA-23/27 can moderate muscle atrophy in streptozotocin (STZ)-induced diabetic mice. Recombinant of adeno-associate virus (rAAV-miR-23/27) was injected into the skeletal muscle of diabetic and normal mice (C57BL/6J, 6–8 weeks). Mice were divided into four groups: control/AAV-ctrl, control/AAV-miR-23/27, diabetes/AAV-ctrl and diabetes/AAV-miR-23/27 (n=12/group). STZ (175 mg/kg) was injected on 2 consecutive days. Muscle and kidney samples were harvested 8 weeks after the injection. Muscle weight was significantly decreased in diabetic mice versus control mice. The expression of both miR-23a-3p and miR-27a-3p increased 15.3- and 13.8-fold, respectively, in muscle from control mice, and increased 12.5-fold (miR-23) and 10.9-fold (miR-27) in diabetic muscle following AAV injections. AAV-miR-23/27 ameliorated the diabetes-induced decrease of tibialis anterior (TA) muscle weight and the TA muscle to body weight ratio. Muscle function was measured using a grip strength meter at the end of experiment. Diabetic mice treated with AAV-miR-23/27 exhibited increased muscle grip capacity compared with diabetic mice (diabetes: 3.2± 0.9 KGF-2; diabetes/miR-23/27: 4.1 ± 0.8 KGF-2; p<0.05). Protein metabolism markers were measured by Western blot and mRNA expression by PCR. Exogenous miR-23-27 blunted the increase in diabetes-induced FoxO1, increased phosphorylation of Akt, and reduced PTEN protein. The protein abundance of two E3 ubiquitin ligases, TRIM63/MuRF1 and FBXO32/atrogin-1, both direct targets of miR23 in the insulin pathway, were attenuated by miR-23/27/24-2. Additionally, it was found that AAV-miR-23/27 lessened myostatin mRNA and protein levels and the downstream signaling of phosphorylated pSmad2/3. In conclusion, AAV-miR-23/27 can prevent diabetes-induced muscle loss by a multi-faceted mechanism. MiR-23 inhibits PTEN, TRIM63/MuRF1 and FBXO32/atrogin-1, thus upregulating insulin-like growth factor and limiting muscle protein loss. MiR-27 directly targets myostatin, resulting in increased myogenesis. This combination can mitigate accelerated proteolysis-related signaling, resulting in prevention of muscle loss induced by diabetes. These results suggest that miR23 and miR27 may serve as effective therapeutic targets for the treatment of diabetes-induced muscle atrophy. Future studies will examine the impact of miR-23/27 on renal fibrosis on diabetes-induced nephropathy. Support or Funding Information This work was supported by: STEP-UP 1R25DK095492-01; NIH/NIAMS R01AR060268; NIH National Institute of Diabetes and Digestive Diseases; The American Physiological Society; and, Dr. Bin Wang, and Dr. Aiqing Zhang at the Emory University School of Medicine. Insulin signaling pathway miR23/27 attenuates the STZ-induced decline in insulin signaling as evidenced by Western blot. miR23/27 attenuates the STZ-induced decline in insulin signaling as found by qPCR. Exogenous miR-23/27 decrease myostatin amount in normal and STZ. Myostatin mRNA was reduced by miR-23/27, as shown by qPCR. Muscle function was increased by miR23/27/24. Average T.A. muscle weight to body weight ratio after tissue extraction. Insulin signaling pathway miR23/27 attenuates the STZ-induced decline in insulin signaling as evidenced by Western blot. miR23/27 attenuates the STZ-induced decline in insulin signaling as found by qPCR. Exogenous miR-23/27 decrease myostatin amount in normal and STZ. Myostatin mRNA was reduced by miR-23/27, as shown by qPCR. Muscle function was increased by miR23/27/24. Average T.A. muscle weight to body weight ratio after tissue extraction.
BibTeX
@article{escobar2017impact,
  author = {Elizabeth Marie Escobar and Xiaonan Wang and Faten Hassounah},
  title = {{The Impact of MicroRNA 23/27 on Muscle Atrophy in Diabetic Mice}},
  journal = {The FASEB Journal},
  year = {2017},
  doi = {10.1096/fasebj.31.1\_supplement.1021.18},
}

Loading related content...

Figure